Basilea Pharmaceutica AG (SWX: BSLN)

Market Cap	489.09M
Revenue (ttm)	149.02M
Net Income (ttm)	-652.00K
Shares Out	12.12M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	9.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,016
Open	39.90
Previous Close	39.75
Day's Range	39.80 - 40.70
52-Week Range	32.00 - 47.95
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumoni...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 147
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2023, Basilea Pharmaceutica AG's revenue was 157.63 million, an increase of 6.68% compared to the previous year's 147.77 million. Earnings were 10.45 million, a decrease of -13.96%.